A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression-Reference-Cited by-同舟云学术

A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression

Published:2019-10-10 Issue:10 Volume:14 Page:e0221635
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Chapeau Emilie A.^ORCID,Mandon Emeline,Gill Jason^ORCID,Romanet Vincent,Ebel Nicolas,Powajbo Violetta,Andraos-Rey Rita,Qian Zhiyan,Kininis Miltos,Zumstein-Mecker Sabine,Ito Moriko,Hynes Nancy E.,Tiedt Ralph,Hofmann Francesco,Eshkind Leonid,Bockamp Ernesto,Kinzel Bernd,Mueller Matthias,Murakami Masato,Baffert Fabienne,Radimerski Thomas

Funder

Novartis

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference59 articles.

1. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders;EJ Baxter;Lancet,2005

2. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera;C James;Nature,2005

3. A gain-of-function mutation of JAK2 in myeloproliferative disorders;R Kralovics;N Engl J Med,2005

4. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis;RL Levine;Cancer Cell,2005

5. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients;AD Pardanani;Blood,2006

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms;Cancer Discovery;2024-01-12

2. Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable;Clinical Cancer Research;2023-11-22

3. A Novel Subtype of Myeloproliferative Neoplasms Driven by a MYC-Alarmin Axis;2023-09-26

4. Biology and therapeutic targeting of molecular mechanisms in MPN;Blood;2022-12-19

5. Jak2^V617F Reversible Activation Shows an Essential Requirement for Jak2^V617F in Myeloproliferative Neoplasms;2022-05-18